These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15159681)

  • 1. Cannabinoid agonists in the treatment of blepharospasm--a case report study.
    Gauter B; Rukwied R; Konrad C
    Neuro Endocrinol Lett; 2004; 25(1-2):45-8. PubMed ID: 15159681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact on quality of life of botulinum toxin treatments for essential blepharospasm.
    MacAndie K; Kemp E
    Orbit; 2004 Dec; 23(4):207-10. PubMed ID: 15590520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, placebo-controlled, crossover clinical trial of super blue-green algae in patients with essential blepharospasm or Meige syndrome.
    Vitale S; Miller NR; Mejico LJ; Perry JD; Medura M; Freitag SK; Girkin C
    Am J Ophthalmol; 2004 Jul; 138(1):18-32. PubMed ID: 15234278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
    Badarny S; Susel Z; Honigman S
    Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Progression of botulinum toxin type A dosage in craniocervical dystonias. An eight year comparative study].
    Echeverría Urabayen A; Fanjul S; Meseguer E; García Ruiz Espiga PJ
    Rev Neurol; 2004 Mar 16-31; 38(6):511-3. PubMed ID: 15054712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Results of long term treatment of essential blepharospasm and facial hemispasm with botulinum toxin A].
    Ziak P
    Cesk Slov Oftalmol; 2004 Jan; 60(1):37-44. PubMed ID: 15011305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial.
    Truong D; Comella C; Fernandez HH; Ondo WG;
    Parkinsonism Relat Disord; 2008; 14(5):407-14. PubMed ID: 18325821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
    Bihari K
    Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of botulinum toxin therapy in otorhinolaryngology: experience from 1,000 treatments.
    Helmstaedter V; Wittekindt C; Huttenbrink KB; Guntinas-Lichius O
    Laryngoscope; 2008 May; 118(5):790-6. PubMed ID: 18300708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supramaximal doses of botulinum toxin for refractory blepharospasm.
    Levy RL; Berman D; Parikh M; Miller NR
    Ophthalmology; 2006 Sep; 113(9):1665-8. PubMed ID: 16828511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electroconvulsive therapy and ocular dystonia.
    Sharma A; Hammer S; Egbert M; Sorrell JH
    J ECT; 2007 Sep; 23(3):181-2. PubMed ID: 17804995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is new in the era of focal dystonia treatment? Botulinum injections and more.
    Cetinkaya A; Brannan PA
    Curr Opin Ophthalmol; 2007 Sep; 18(5):424-9. PubMed ID: 17700237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy of dystonia in Japan].
    Mezaki T; Hayashi A; Nakase H; Hasegawa K
    Rinsho Shinkeigaku; 2005 Sep; 45(9):634-42. PubMed ID: 16248394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin improves the quality of life and reduces the intensification of depressive symptoms in patients with blepharospasm.
    Ochudlo S; Bryniarski P; Opala G
    Parkinsonism Relat Disord; 2007 Dec; 13(8):505-8. PubMed ID: 17543569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dystonias: what the practitioner needs to know].
    von Dengler R; Rollnik JD
    MMW Fortschr Med; 2004 Nov; 146(48):44-6. PubMed ID: 15625936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024).
    Racette BA; Stambuk M; Perlmutter JS
    Mov Disord; 2002 Sep; 17(5):1098-100. PubMed ID: 12360571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dystonic frowning without blepharospasm.
    Hirota N; Hirota M; Mezaki T
    Parkinsonism Relat Disord; 2008 Nov; 14(7):579-80. PubMed ID: 18316230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
    Wissel J; Entner T
    Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life in patients with focal dystonia.
    Pekmezovic T; Svetel M; Ivanovic N; Dragasevic N; Petrovic I; Tepavcevic DK; Kostic VS
    Clin Neurol Neurosurg; 2009 Feb; 111(2):161-4. PubMed ID: 18995953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dronabinol (delta9-tetrahydrocannabinol) in long-term treatment. Symptom control in patients with multiple sclerosis and spasticity, neuropathic pain, loss of appetite and cachexia].
    Nauck F; Klaschik E
    Schmerz; 2004 Dec; 18 Suppl 2():S26-30. PubMed ID: 23570087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.